These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29739754)

  • 1. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.
    Panch SR; Bozik ME; Brown T; Makiya M; Prussin C; Archibald DG; Hebrank GT; Sullivan M; Sun X; Wetzler L; Ware J; Fay MP; Dunbar CE; Dworetzky SI; Khoury P; Maric I; Klion AD
    Blood; 2018 Aug; 132(5):501-509. PubMed ID: 29739754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.
    Laidlaw TM; Prussin C; Panettieri RA; Lee S; Ferguson BJ; Adappa ND; Lane AP; Palumbo ML; Sullivan M; Archibald D; Dworetzky SI; Hebrank GT; Bozik ME
    Laryngoscope; 2019 Feb; 129(2):E61-E66. PubMed ID: 30284267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.
    Dworetzky SI; Hebrank GT; Archibald DG; Reynolds IJ; Farwell W; Bozik ME
    Blood Cells Mol Dis; 2017 Mar; 63():62-65. PubMed ID: 28178599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.
    Siddiqui S; Wenzel SE; Bozik ME; Archibald DG; Dworetzky SI; Mather JL; Killingsworth R; Ghearing N; Schwartz JT; Ochkur SI; Jacobsen EA; Busse WW; Panettieri RA; Prussin C
    J Allergy Clin Immunol; 2023 Nov; 152(5):1121-1130.e10. PubMed ID: 37277072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benralizumab for
    Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
    N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
    Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.
    Bozik ME; Mather JL; Kramer WG; Gribkoff VK; Ingersoll EW
    J Clin Pharmacol; 2011 Aug; 51(8):1177-85. PubMed ID: 20959524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
    Stokes K; Yoon P; Makiya M; Gebreegziabher M; Holland-Thomas N; Ware J; Wetzler L; Khoury P; Klion AD
    Clin Exp Allergy; 2019 Dec; 49(12):1598-1604. PubMed ID: 31657082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW; Ring J; Huss-Marp J; Kahn JE
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.
    Dispenza MC; Bochner BS
    Curr Hematol Malig Rep; 2018 Jun; 13(3):191-201. PubMed ID: 29680938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic hypereosinophilic syndrome: a rare but fatal condition presenting with common symptoms.
    Osowo A; Fetten J; Navaneethan S
    South Med J; 2006 Feb; 99(2):188-9. PubMed ID: 16509562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
    Cheah BC; Kiernan MC
    IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The hypereosinophilic syndrome: case report].
    Mikołajczyk K; Zaba R; Walkowiak B; Grzybowski G; Samborski W
    Ann Acad Med Stetin; 2006; 52 Suppl 2():65-9. PubMed ID: 17471838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
    Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
    J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexpramipexole: a new antieosinophil drug?
    Gleich GJ
    Blood; 2018 Aug; 132(5):461-462. PubMed ID: 30072411
    [No Abstract]   [Full Text] [Related]  

  • 19. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood idiopathic hypereosinophilic syndrome: report of a case.
    Kao CC; Ou LS; Lin SJ; Huang JL
    Asian Pac J Allergy Immunol; 2002 Jun; 20(2):121-6. PubMed ID: 12403197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.